LAUSR

Understanding the immune responses elicited by severe acute respiratory syndrome virus (SARS‐CoV‐2) infection is critical to public health policy and vaccine development and prevention of reinfections for COVID‐19. It is important to know the neutralizing capacity of antibodies and to monitor their persistence. Patients with COVID‐19 were divided into four groups (severe‐critical, moderate, mild, and asymptomatic) according to their clinical severity. Antibodies against SARS‐CoV‐2 spike viral surface protein were investigated by ELISA method 3 and 9 months after the onset of the disease. Neutralizing antibody (NAb) response was evaluated by microneutralization test. Patients who received at least two doses of COVID‐19 vaccine after illness were enrolled. SARS‐CoV‐2 immunoglobulin G (IgG) and NAb titers were shown to be strongly correlated with disease severity. Anti‐SARS‐CoV‐2 IgG and NAb levels were found to be compatible with each other. After 9 months of follow‐up, both IgG and NAb levels continued unabated in individuals who had the disease. In individuals who received at least two doses of the vaccine, these levels increased, except for severe‐critical patients. High levels of anti‐SARS‐CoV‐2 IgG are indicative, as it is difficult to investigate NAb in routine laboratories. At the same time, it can be predicted that this period may be much longer if it continues for at least 9 months and is reinforced with vaccination.